XOMA Royalty Corporation (NASDAQ:XOMA) Receives Average Rating of “Moderate Buy” from Analysts

XOMA Royalty Corporation (NASDAQ:XOMA) has been given an average recommendation of “Moderate Buy” by the six ratings firms that are covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $60.60.

A number of analysts recently issued reports on the company. HC Wainwright decreased their target price on XOMA Royalty from $104.00 to $97.00 and set a “buy” rating for the company in a research report on Thursday, December 11th. Wall Street Zen downgraded XOMA Royalty from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Leerink Partners lowered their target price on shares of XOMA Royalty from $58.00 to $45.00 and set an “outperform” rating on the stock in a research report on Thursday, December 11th. Stifel Nicolaus set a $50.00 price target on shares of XOMA Royalty in a research report on Friday, December 12th. Finally, Zacks Research upgraded shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a research note on Monday, February 9th.

Insider Buying and Selling at XOMA Royalty

In related news, CEO Owen Hughes purchased 100,000 shares of the stock in a transaction that occurred on Thursday, December 4th. The shares were purchased at an average price of $25.05 per share, with a total value of $2,505,000.00. Following the completion of the acquisition, the chief executive officer directly owned 102,000 shares in the company, valued at $2,555,100. This represents a 5,000.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 7.20% of the company’s stock.

Institutional Trading of XOMA Royalty

A number of hedge funds have recently added to or reduced their stakes in XOMA. Vanguard Group Inc. grew its stake in shares of XOMA Royalty by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 668,111 shares of the biotechnology company’s stock valued at $25,749,000 after purchasing an additional 29,298 shares during the last quarter. Opaleye Management Inc. lifted its holdings in shares of XOMA Royalty by 14.7% during the fourth quarter. Opaleye Management Inc. now owns 292,590 shares of the biotechnology company’s stock worth $7,780,000 after purchasing an additional 37,503 shares during the period. Geode Capital Management LLC grew its position in XOMA Royalty by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 221,566 shares of the biotechnology company’s stock valued at $5,893,000 after buying an additional 9,589 shares during the last quarter. Woodline Partners LP increased its stake in XOMA Royalty by 16.5% in the 3rd quarter. Woodline Partners LP now owns 209,945 shares of the biotechnology company’s stock valued at $8,091,000 after buying an additional 29,715 shares during the period. Finally, State Street Corp increased its stake in XOMA Royalty by 4.7% in the 4th quarter. State Street Corp now owns 174,908 shares of the biotechnology company’s stock valued at $4,651,000 after buying an additional 7,873 shares during the period. 95.92% of the stock is owned by institutional investors and hedge funds.

XOMA Royalty Stock Performance

NASDAQ XOMA opened at $25.32 on Tuesday. The company has a fifty day moving average of $25.93 and a two-hundred day moving average of $31.09. The company has a market capitalization of $313.46 million, a PE ratio of 34.22 and a beta of 0.86. XOMA Royalty has a 1 year low of $18.35 and a 1 year high of $39.92. The company has a debt-to-equity ratio of 1.07, a current ratio of 3.91 and a quick ratio of 3.91.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.